Press Esc to close

Welcome to Money Morning - Only the News You Can Profit From.

Close

This Says Our Favorite Biotech Is Off to the Races

Shares of a promising biotech we recommended back in February 2013 – jumped as much as 27% to a three-month high of $14.20 yesterday after the company said a new cancer drug met its main goal in a midstage clinical trial.

Its shares backtracked a bit as the day progressed but still closed 17.6% higher for the session. These shares have advanced 361% since we first told you about them. The stock has generated a peak gain of 456%, making it one of the 31 recommendations we’ve made to you that have doubled or better since we launched Private Briefing in August 2011. (More on that later…)

  • This Alzheimer's "Pacemaker" Could Be the Bridge to a Cure There's good news for Alzheimer's patients after all...

    This news comes at an opportune time. Just last summer, the whole effort suffered a major setback.

    That's when three Big Pharma firms said they were halting development of Alzheimer's compounds because the medicines simply didn't work. No doubt, that was a blow for both patients and investors in Eli Lilly & Co. (NYSE:LLY), Pfizer Inc. (NYSE:PFE), and Johnson & Johnson (NYSE:JNJ).

    But this month we learned that a research team at Johns Hopkins has for the first time implanted a promising device into the brain of a U.S. Alzheimer's patient. It seems to combat the effects of Alzheimer's by providing deep-brain stimulation. It works very much like the pacemaker that's normally used in the heart.

    Over the next year or so, a total of 40 patients will receive the implants under a federally funded trial.

    This is a big move with very promising potential. You see, doctors have used a similar device to control Parkinson's disease for about the past 15 years, with some 80,000 patients receiving the implants. They report having fewer seizures and needing less medication.

    I believe this very well could be the bridge technology we need until a true "cure" for Alzheimer's is found. Right now, the chances look good that this interim step will succeed.

    "This is a very different approach, whereby we are trying to enhance the function of the brain mechanically," says Dr. Paul B. Rosenberg. "It's a whole new avenue for potential treatment for a disease becoming all the more common with the aging of the population."

    As high-tech investors, we need to keep an eye on this research and be ready to pounce when a medical-device maker gets it to market.

    I don't know just when that will happen. But when it does, you can bet that I'll drop you a line.

    Meantime, I have four more fascinating developments to share with you today.

    Take a look...

    To continue reading, please click here... Read More...